Celltrion (068270) 🔎 In-depth
KOSPI · Price as of 2026-08-06 · Updated 2026-08-09
Celltrion develops and manufactures biosimilars — versions of antibody drugs whose patents have expired, built to deliver the same effect — and supplies Europe and the United States through its own sales network, with biologics such as Remsima, Yuflyma and Zymfentra generating 94% of revenue. Second-quarter 2026 revenue rose 45.0% from a year earlier to ₩1.3937 trillion and operating profit rose 86.3% to ₩451.8 billion, so first-half operating profit alone already reached 66% of last year's full-year figure. The notable point recently is that a rising share of in-house production together with growing new-product sales has lifted the quarterly operating margin in steps, while follow-on products such as the Cosentyx and Darzalex biosimilars are still in regulatory review and clinical trials, so their outcomes could change the pace of growth.
This page organises public market and filing data for information purposes. It is not a recommendation to buy or sell, nor investment advice. Metrics labelled “forward” are our own unverified estimates. Please verify with the original DART filings and decide at your own responsibility.
30-second brief
Pulled directly from the computed values below — not a separately written opinion.
What do the SourceComputedEstimateReading tags mean?
Source filings and exchange data · Computed calculated from public data · Estimate our own unverified projection · Reading drafted automatically, then rule-checked. See AI & Automation.
Core valuation metric
This stock's effective sub-sector is “CDMO & Biosimilars” (Biotech & Pharmaceuticals), a type typically read first through forward P/E.
CDMO and biosimilar players see future utilization and profit hinge on large capacity build-outs and new supply contracts. Because it is the earnings still to come — reflecting fresh orders and added capacity — that drives the price, forward P/E, based on expected earnings, is the first lens.
Price against earnings alone becomes unstable when earnings swing. Reading it together with price against assets helps gauge the downside.
This note explains how each sector is typically valued and is educational context only, not investment advice.
At-a-glance assessment financial health · growth · profitability · valuation
- Debt ratio, current ratio and interest burden all look healthy.
- Revenue rose 17.0% year over year, and the pace is slowing (3-year trend: rising).
- Most recent quarter (Q1 2026) revenue was 36.0% higher than a year earlier.
- ROE is 7.2% (controlling-interest basis). It is above the sector average.
- Operating margin is 30.0%.
- A sector-metric and in-depth research verdict — see “Valuation vs peers” below for the basis.
Ownership & governance As of 2015-12-31
Largest shareholder Celltrion Holdings 19.41% (corporate)
Controlling bloc incl. related parties 21.6%
With the controlling bloc holding 22%, control is maintained but the free float is relatively large.
🔎 In-depth analysis Reading
Celltrion develops, manufactures and markets biosimilars — drugs built to match the efficacy and safety of antibody medicines whose patents have expired. As of the first quarter of 2026, biologics accounted for 94.0% of revenue, with chemical drugs such as Godex at 5.99%. Its main products include the autoimmune treatments Remsima, Yuflyma, Steqeyma and Avtozma; the cancer treatments Truxima, Herzuma and Vegzelma; the allergy treatment Omlyclo; the eye-disease treatment Eydenzelt; and the osteoporosis and bone-metastasis treatments Stoboclo and Osenvelt. The company has secured global marketing approvals for 11 biosimilars to date, and to those it adds Zymfentra (CT-P13 SC), the world's first subcutaneous formulation of infliximab. Zymfentra is not a biosimilar but a product approved as a new drug in the United States, so its pricing structure is different. Distribution matters especially in how the money is made. Europe switched to direct sales for all products in the second half of 2022, and the United States moved to a direct sales structure in 2023. That means margin once handed to intermediate distributors is now kept by the company, and it is one pillar of the recent rise in profitability. Production runs on 250,000 liters of capacity in Korea and the 66,000-liter drug substance plant in Branchburg, whose acquisition was completed in December 2025. Branchburg serves as the US supply base for the company's own products while also carrying out contract manufacturing for other companies.
The latest close is ₩195,000 and the market capitalization is ₩45.3 trillion. The price sits above its 20-day moving average (₩178,895) and above its 60-day moving average (₩179,027). It holds above both its short- and medium-term moving averages, so the trend looks healthy. The RSI (a supplementary indicator that gauges the strength of gains versus losses over the past 14 days on a 0-100 scale) is 65.0, a neutral level. The one-month change is +9.4%, the three-month change is +0.1%, and the position relative to the 52-week high is -21.5%. Relative strength versus the KOSPI is 41 (on a 1-99 scale, converted from returns against the index over the past year with more weight on recent performance; higher means stronger than the market). It is stronger than roughly 41% of all stocks. Over the past three months it outpaced the index by 14.5%. Chart interpretation is best done alongside trading volume and the dates on which disclosures occur.
On confirmed 2025 figures, revenue was ₩4.1625 trillion, operating profit ₩1.1685 trillion and net profit attributable to controlling interests ₩1.0296 trillion. The operating margin of 28.1% is far above the manufacturing average. The balance sheet is stable: a debt-to-equity ratio of 28.9%, a current ratio of 139.3% and interest coverage (how many times operating profit covers interest expense) of 12.1x. ROE (net profit relative to shareholders' equity) looks low at 6.0%, and there is a reason. A merger at the end of 2023 lifted shareholders' equity to ₩17.2 trillion, and of ₩22.3 trillion in assets, ₩13.8 trillion (62%) is intangible. With a large denominator and profit only now recovering, the ratio looks compressed. Net profit attributable to controlling interests of ₩716.3 billion in the first half of 2026 points ROE in an improving direction. Turned around, though, a P/B of 2.51x (how many times book net assets the share price represents) is calculated on net assets that are mostly intangible, and that belongs in the picture too. For a company like this, where future profit shifts sharply with capacity additions and new product approvals, the first thing to look at is the forward P/E (how many times expected profit the share price represents) rather than past results. We recalculated that metric directly. Taking the ₩45.3 trillion market capitalization together with confirmed first-half net profit attributable to controlling interests of ₩716.3 billion and the seasonal pattern in which second-half 2025 revenue was 1.31x the first half gives 27-29x. That does not conflict with this deep-dive estimate of 27.8x. On confirmed results, by contrast, the P/E is 41.98x. Enterprise value metrics are worth a look as well. EV is market capitalization plus net debt, close to the price of acquiring the whole company. Net debt is negative ₩1.1192 trillion — a net cash position with more cash than debt — and EV is ₩39.9 trillion. On confirmed 2025 results that gives EV/EBIT (how many times operating profit enterprise value represents) of 34.2x, EV/EBITDA of 27.4x and EV/Sales of 9.6x. All rest on last year's earnings, so they fall with a lag once this year's profit is reflected. Cash-flow appeal is still weak. Free cash flow (operating cash minus capital expenditure) is ₩314.3 billion, a 0.77% free-cash-flow yield on market capitalization, because large outlays are under way — new plants 4 and 5 in Songdo (180,000 liters in total, with expected investment of about ₩1.2265 trillion) and the Branchburg plant acquisition among them. The dividend yield is 0.41% and the payout ratio is 15.9%. One accounting caveat belongs here. Research and development spending was ₩122.4 billion in the first quarter of 2026 (10.7% of revenue) and ₩482.4 billion in 2025, of which roughly half is capitalized as development assets. Because it is not all expensed in the year it is spent, accounting profit can look better than the actual cash going out.
Start with the three-year arc. Revenue grew from ₩2.1764 trillion (2023) to ₩3.5573 trillion (2024) and ₩4.1625 trillion (2025), a five-year average growth rate of 21.8% a year. Operating profit, by contrast, dipped once before coming back: ₩651.5 billion (2023) → ₩492.0 billion (2024) → ₩1.1685 trillion (2025). The 2024 weakness came from amortization arising when inventory was remeasured at fair value in the merger at the end of 2023, and profit normalized in 2025 as that burden cleared. The quarterly trend matters most right now. First-quarter 2026 revenue was ₩1.145 trillion (+36.0% year on year) with operating profit of ₩321.9 billion (+115.4%), and second-quarter revenue was ₩1.3937 trillion (+45.0%) with operating profit of ₩451.8 billion (+86.3%). Revenue rose 36-45% year on year in two consecutive quarters. The margin picture is sharper still: the quarterly operating margin climbed in steps from 17.7% in the first quarter of 2025 to 32.4% in the second quarter of 2026. Three things converged to produce that rise. First, the inventory amortization burden created in the merger has run its course. Second, costs fell as in-house production replaced contract manufacturing. Third, high-margin new products such as Zymfentra, Eydenzelt and Stoboclo took a larger share. On the volume side, US prescriptions expanded and European tender wins increased together. The basis for viewing the full year is this. First-half cumulative revenue was ₩2.5387 trillion (+40.8%) and operating profit ₩773.7 billion (+97.4%), so half a year alone already reached 66% of 2025 full-year operating profit. On top of that, this company is structurally bigger in the second half. In 2025 as well, second-half revenue was 1.31x first-half revenue of ₩1.8034 trillion, and operating profit was 1.98x. That comes from European tender volumes and US prescriptions clustering in the second half. So even assuming a more conservative second-half skew than in past years, this year's profit rises sharply against 2025. The forward P/E on that profit is 27.8x. The figure is not a mechanical quadrupling of one quarter's results but an estimate built up quarter by quarter from two confirmed quarters plus the margin structure by product and the verified seasonal skew.
Filings have been unusually numerous over the past three months, and they split clearly by character. On results, preliminary consolidated second-quarter 2026 figures were confirmed in an amended filing on 27 July 2026. It was an upward revision: the actual numbers came in better than the initial 3 July disclosure (revenue of ₩1.3 trillion and operating profit of ₩430 billion). On products, marketing applications for CT-P55 (a Cosentyx biosimilar) were filed in three regions in succession — Korea on 26 June, Europe on 24 July and the United States on 30 July — covering six indications including plaque psoriasis, psoriatic arthritis and ankylosing spondylitis. On 24 July the company filed phase 3 clinical trial plans in Korea, the United States and Europe simultaneously to extend Zymfentra's indications to rheumatoid arthritis. On 28 May it applied for Korean marketing approval of a subcutaneous formulation of Herzuma. There was news in the other direction too. On 14 July the company ended the European phase 3 trial of CT-P51 (a Keytruda biosimilar) early and voluntarily withdrew the trial plan. The reason it gave was that a shift in the regulatory environment for biosimilar trials led it to adjust strategy toward a smaller number of subjects, and in that process EU countries dropped out of the participating list. Patient recruitment had already finished and the trial continues in participating countries outside the EU. Shareholder returns followed one after another. At a board meeting on 21 May the company approved both a bonus issue of 0.05 new shares per share (10,920,342 new shares, record date 5 June, listing 30 June) and a ₩100 billion treasury share acquisition; an acquisition results report on 30 June showed 586,927 shares acquired for ₩99.8 billion, fulfilling the plan. Earlier in May, the cancellation of 488,977 treasury shares took effect. On facilities, a plan to build plants 4 and 5 at the Songdo campus is under way, totaling 180,000 liters with expected investment of about ₩1.2265 trillion.
Start with what is worth observing. First, the margin improvement is confirmed in numbers rather than words. The quarterly operating margin rose from 17.7% in the first quarter of 2025 to 32.4% in the second quarter of 2026. It reflects the merger inventory amortization burden running its course, a larger share of in-house production and a bigger contribution from high-margin new products, and none of those three reverses easily. Second, because the company sells directly in Europe and the United States, more sales leave more margin with the company. Volume growth translates straight into profit growth. Third, the P/E of 41.98x on confirmed results looks demanding, but with profit rising fast it falls to 27.8x on this year's earnings — inside the 23-37x trailing P/E band of the large Korean pharmaceutical and biotech comparison group. Fourth, shareholder returns are at the execution stage: a 5% bonus issue, ₩99.8 billion of completed treasury share acquisitions and the cancellation of 488,977 treasury shares were all processed within the past three months. The cautions are equally clear. First, the second-quarter results are preliminary figures that the external auditor has not finished reviewing. They may differ from the final numbers. Second, first-quarter net profit growth (+222.9%) looks far larger than operating profit growth (+115.4%), and about ₩110 billion arriving from outside operations sits inside that — the difference between first-quarter pre-tax profit of ₩432.2 billion and operating profit of ₩321.9 billion. It is safer to assume that part does not repeat. Third, the follow-on products have not produced results yet. CT-P44 (Darzalex), CT-P53 (Ocrevus), CT-P55 (Cosentyx) and CT-P51 (Keytruda) are all in phase 3 trials or regulatory review. CT-P51 in particular had its European phase 3 trial ended early and withdrawn voluntarily. The company called it a strategic adjustment, but the possibility of a delayed timetable remains. Fourth, 62% of assets — ₩13.8 trillion — is intangible. Because those assets came across in the merger, a P/B of 2.51x means a far higher multiple against tangible net assets. Fifth, the free-cash-flow yield is low at 0.77%. Until the Songdo plants 4 and 5 expansion is finished, money earned goes back out into facilities. Sixth, biosimilars are a market where prices fall as more competitors arrive. It is hard to assume today's high margins hold unchanged for years. Changes in US drug pricing policy are a variable as well. In sum, the substance of the earnings improvement is confirmed and the multiple on this year's profit sits inside the peer band. That multiple rests on the second-half seasonal skew appearing as it has in past years, however, and the follow-on products that would extend growth are still standing at the threshold of approvals and trials.
🔎 Valuation vs peers Fairly valued
Selected from large Korean bio and pharmaceutical companies that obtain approvals and market their products directly worldwide and that are comparable in market capitalization and business character. Samsung Biologics is the touchpoint on biologics development and manufacturing, SK Biopharmaceuticals on the structure of marketing one's own new drugs, and Hanmi Pharmaceutical and Yuhan serve as the baseline for large traditional pharmaceutical companies.
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Samsung Biologics | 39.28x | 8.85x | 23.70% |
| SK Biopharmaceuticals | 24.50x | 7.02x | 37.56% |
| Hanmi Pharmaceutical | 29.54x | 3.85x | 13.54% |
| Yuhan Corporation | 31.93x | 2.71x | 9.06% |
(a) Position versus the peer set first. Celltrion's forward P/E on this year's earnings is 27.8x. Trailing P/E ratios across the peer set form a 23-37x band: Samsung Biologics at 36.9x, Yuhan at 30.2x, Hanmi Pharmaceutical at 26.1x and SK Biopharmaceuticals at 23.0x. At 27.8x it sits right in the middle. On P/B, Celltrion's 2.35x is far below Samsung Biologics at 8.84x and SK Biopharmaceuticals at 7.55x, and close to Yuhan at 2.48x. (b) Premium and discount factors exist on both sides. On the premium side are the direct sales structure and internalized production. Keeping the distribution margin and reducing reliance on contract manufacturing lifted the quarterly operating margin from 17.7% to 32.4% in a little over a year, and that improvement is already confirmed in results. On the discount side is the nature of the assets. With ₩13.8 trillion of ₩22.3 trillion in assets intangible (62%), a P/B of 2.51x is a far higher multiple measured against tangible net assets, and ROE of 6.0% is on the low side within the peer set. A free-cash-flow yield of 0.77% also has limited room to improve until the capacity expansion is finished. (c) Judging on confirmed results alone distorts the picture. On last year's confirmed results the P/E is 41.98x and EV/EBIT is 34.2x, at the top of the peer set. But the denominator of those multiples — 2025 profit — still carried the merger inventory amortization burden. Actual results after that burden cleared show first-half 2026 operating profit of ₩773.7 billion (+97.4% year on year), filling 66% of last year's full-year figure in half a year. Allowing for a seasonal structure that is larger in the second half (2025 second-half revenue was 1.31x the first half and operating profit 1.98x), the multiple on this year's earnings comes down to 27.8x. Taken together, it sits inside the peer band, so we view it as fairly valued. That judgment rests on two premises: that the second-half seasonal skew appears at its usual level, and that the preliminary second-quarter figures do not differ greatly from the final ones. For reference, this site's baseline diagnostic viewed the valuation as high against the sector-wide median, but narrowing the comparison from the whole sector to large bio companies with global commercialization capability moves the position to the middle of the band. Because it depends on which yardstick is used, both views are set down here.
Price history Close · MA20 · MA60
The latest close is ₩195,000 and the market capitalization is ₩45.3 trillion. The price sits above its 20-day moving average (₩178,895) and above its 60-day moving average (₩179,027). It holds above both its short- and medium-term moving averages, so the trend looks healthy. The RSI (a supplementary indicator that gauges the strength of gains versus losses over the past 14 days on a 0-100 scale) is 65.0, a neutral level. The one-month change is +9.4%, the three-month change is +0.1%, and the position relative to the 52-week high is -21.5%. Relative strength versus the KOSPI is 41 (on a 1-99 scale, converted from returns against the index over the past year with more weight on recent performance; higher means stronger than the market). It is stronger than roughly 41% of all stocks. Over the past three months it outpaced the index by 14.5%. Chart interpretation is best done alongside trading volume and the dates on which disclosures occur.
Relative performance stock vs index · start = 100
Excess return vs index · 3M +14.55% / 6M -24.49% / 12M -44.04%
Key metrics Computed vs sector median
Valuation
The P/E of 41.98x is above the sector median (15.02x). The P/B of 2.57x is above the sector median (1.10x). That said, this P/E is based on last year's (trailing) results. With recent quarterly earnings up sharply, the trailing P/E can look higher than it really is, so a precise read is best done on this year's expected (forward) earnings.
Enterprise value (EV)
EV = market cap + net debt. It reflects cash and debt, so it captures the real cost of the whole business that market cap alone misses; lower multiples are cheaper relative to earnings or sales.
Profitability & financials
Return on equity (ROE) is 7.2%, above the sector average (1.0%). The operating margin is 30.0%. The debt ratio is 30.2%, so the financial structure is stable.
Growth FY2025 · annual report (consolidated)
| Item | 2023 | 2024 | 2025 | YoY |
|---|---|---|---|---|
| Revenue | $1.5B | $2.5B | $2.9B | +17.01% ↓ slower |
| Operating profit | $457.7M | $345.6M | $820.9M | +137.49% ↑ faster |
| Net profit | $376.3M | $296.9M | $723.3M | +143.58% ↑ faster |
| 5-year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $1.3B | $1.6B | $1.5B | $2.5B | $2.9B |
| Operating profit | $522.8M | $454.7M | $457.7M | $345.6M | $820.9M |
| Net profit | $407.1M | $377.8M | $376.3M | $296.9M | $723.3M |
| Revenue CAGR | 4-yr avg 21.77% | ||||
Revenue rose 17.0% year over year (2023 ₩2.2 trillion → 2024 ₩3.6 trillion → 2025 ₩4.2 trillion), and the three-year trend is 'rising'. That said, the pace of growth slowed from the prior year. Operating profit rose 137.5% year over year. Profit is growing at an accelerating pace. Over the 5 years on record, revenue compound annual growth (CAGR) is 21.8%. The two-year revenue CAGR is 38.3%. In the most recent quarter (Q1 2026), revenue was 36.0% higher than the same period a year earlier.
Latest quarterly results Source Q1 2026 · vs year-ago
Technical indicators Computed
What stands out
- Revenue grew 17.0% year over year, a sign of growth.
- The balance sheet is stable in terms of debt and liquidity.
Points to watch
- The price is high versus peers, so expectations already appear priced in.
Recent news & events searched · sourced
- 2026-07-27EarningsAmended preliminary consolidated second-quarter 2026 results — revenue of ₩1.3937 trillion, operating profit of ₩451.8 billion and net profit attributable to controlling interests of ₩370.2 billionRevenue rose 45.0% and operating profit 86.3% year on year. It was an upward revision from the initial 3 July disclosure (revenue of ₩1.3 trillion and operating profit of ₩430 billion). First-half cumulative revenue of ₩2.5387 trillion (+40.8%) and operating profit of ₩773.7 billion (+97.4%) already reached 66% of 2025 full-year operating profit. The quarterly operating margin was 32.4%. Source
- 2026-07-30FilingUS FDA marketing application filed for CT-P55 (a Cosentyx biosimilar)It covers six indications: plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, enthesitis-related arthritis and hidradenitis suppurativa. In the phase 1 study (172 subjects), the 90% confidence intervals for the primary endpoints of AUC and maximum blood concentration fell within the pre-specified equivalence margins. Applications were filed earlier in Korea on 26 June and Europe on 24 July, so three regional reviews are running at once. No review decisions have been issued yet. Source
- 2026-07-24FilingPhase 3 trial plans for Zymfentra (CT-P13 SC) in rheumatoid arthritis filed simultaneously in Korea, the United States and EuropeThe design covers 296 subjects over a 52-week treatment period, confirming superiority to placebo on ACR50 at week 12. Zymfentra is already approved in the United States and Europe for ulcerative colitis and Crohn's disease, and this is an attempt to widen the prescribing range by adding indications. It is currently at the trial-plan application stage. Source
- 2026-07-14UpdateEuropean phase 3 trial of CT-P51 (a Keytruda biosimilar) ended early and the trial plan voluntarily withdrawnThe European portion of a global phase 3 trial in non-small cell lung cancer was halted. The reason the company gave is that a change in the regulatory environment for biosimilar trials led it to shift strategy toward fewer subjects, and as a result EU countries were excluded from the participating list. Patient recruitment had already finished and the trial continues in participating countries outside the EU. It is a matter that could change the timetable for the follow-on pipeline. Source
- 2026-06-30FilingTreasury share acquisition results report — 586,927 shares acquired for ₩99.87281 billionThe shares were acquired on the open market between 8 and 26 June at an average price of ₩170,162. That effectively completed the ₩100 billion plan approved on 21 May. The stated purpose was price stability and enhancing shareholder value, and the expected holding period is at least six months from the final acquisition date. Source
- 2026-05-21DividendBonus issue approved — 0.05 new shares per share, 10,920,342 new shares issuedThe record date for the new share allocation is 5 June and the listing date is 30 June, funded from share premium. Adding the new shares to the 221,633,364 shares outstanding before the issue brings the total to 232,553,706. A treasury share acquisition was approved on the same day, and the cancellation of 488,977 treasury shares took effect as of 21 May. Source
- 2026-05-15FilingFirst-quarter 2026 report — disclosing details of new Songdo plants 4 and 5 and the acquisition of the Branchburg plant in the United StatesNew plants 4 and 5 in Songdo will total 180,000 liters with expected investment of about ₩1.2265 trillion. The 66,000-liter drug substance plant in Branchburg, whose acquisition was completed in December 2025, operates as the company's US supply base and as a contract manufacturing site for other companies. Internalizing production raises cost competitiveness, but capital spending continues until then. Source
Figure cross-check computed ↔ external
| Metric | Computed | External | Status | Source |
|---|---|---|---|---|
| Second-quarter 2026 operating profit | 2026 1 (operating profit ₩321.9 billion) | ₩451.8 billion | Confirmed | link |
| Forward P/E (the first metric to look at in this sub-sector) recalculated | 27.8x | 27~29x | Confirmed | link |
| Degree of second-half 2025 revenue skew | 1.23x | 1.31x | Confirmed | link |
| Total shares outstanding | 232,553,706 | 221,633,364 + 10,920,342 = 232,553,706 | Confirmed | link |
| Net debt (net cash) | 1 ₩119.2 billion | 2025 1 ₩119.2 billion | Unverified | link |
| Existence of out-licensing agreements | — | — | Confirmed | link |
Recent filings Source
- 2026-06-04OwnershipOwnership-change filing
- 2026-06-01Large-business-group status disclosure
- 2026-05-29Corporate governance report
- 2026-05-29OwnershipOfficers'/major-shareholders' holdings report
- 2026-05-28Disclosure
- 2026-05-21TreasuryMaterial-fact report
- 2026-05-21Material-fact report
- 2026-05-21OwnershipOfficers'/major-shareholders' holdings report
- 2026-05-15PeriodicQuarterly report
- 2026-05-12Disclosure
- 2026-05-11Paid-in capital increase (amended)
- 2026-05-11Amended filing
📖 Plain-language glossary — expand if you are new to this
- P/E
- How many times a year's net profit the price is worth (lower is cheaper relative to earnings). The P/E here is on trailing (last full-year) results; for companies whose earnings swing fast (memory chips and other cyclicals/high-growth), a forward P/E on this year's expected earnings is more accurate.
- P/B
- Price relative to net assets (equity). Around 1x means it trades near book value; below 1x means below book.
- P/S
- Price relative to a year's revenue — useful for growth companies with thin earnings.
- Net debt / EV
- Net debt = interest-bearing debt − cash. Negative means more cash than debt (net cash). EV (enterprise value) = market cap + net debt, closer to what it would cost to buy the whole business.
- EV/EBIT · EV/EBITDA · EV/Sales
- Enterprise value against operating profit (EBIT), EBITDA, or revenue. Unlike P/E these reflect debt and cash; lower is cheaper relative to earnings power or sales.
- FCF / FCF yield
- Free cash flow = operating cash − capex, the cash actually left over. FCF yield = FCF ÷ market cap; higher means more cash generated per unit of market value.
- Intrinsic value (DCF)
- Future free cash flow (or, for some capex-heavy but profitable names, forecast earnings) discounted to today to estimate per-share value. Because it shifts a lot with the discount-rate and growth assumptions, it is shown as a bear/base/bull range, and the basis and assumptions are disclosed in one line beneath it.
- ROE
- How much profit the company earns in a year on its equity (%). Higher means better returns on capital.
- EPS / BPS
- Earnings per share / net assets (book value) per share.
- Operating / net margin
- Profit left from the core business / final profit after tax and interest, per unit of revenue.
- Debt ratio
- Debt relative to equity (%). Higher means more reliance on borrowing (norms vary by sector).
- Current ratio
- Assets convertible to cash within a year against debt due within a year. Above 100% leaves some short-term headroom.
- Interest coverage
- How many times operating profit covers the interest owed. Below 1x means operating profit alone struggles to cover interest.
- Dividend yield / payout ratio
- The year's dividend as a % of today's price / the share of earnings paid out as dividends.
- Revenue CAGR
- Multi-year growth expressed as a single yearly average (compound annual growth rate).
- RSI (short-term signal)
- Whether recent price action is overheated or beaten down. Above 70 is overbought, below 30 oversold.
- MA20 / MA60 (moving averages)
- The 20- and 60-day average price. Price above them signals a firmer short-term trend.
- vs 52-week high
- How far below the past year's peak the price sits now (%).
All figures are for reference only; how they read varies by sector and over time.
Sources: Korea FSC market-price API (data.go.kr), OpenDART, KRX/KIND — public data only.
Bong Stocks presents public-data-based information for reference only. It is not investment advice and contains no target prices, ratings, or buy/sell recommendations. Verify independently before making any decision.